The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Multiple myeloma at ASH 2015: New therapeutic opportunities
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, summarises data on emerging treatment options for patients with multiple myeloma.
In newly diagnosed patients, highlights include results from IFM/DFCI 2009, a phase 3 clinical trial investigating autologous transplantation; IFM 2013-04, a phase 3 clinical trial of bortezomib, thalidomide and dexamethasone (VTD) versus bortezomib, cyclophosphamide and dexamethasone (VCD); and SWOG S0777, a phase 3 clinical trial of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone. In relapsed/refractory patients, promising results were observed in trials of new daratumumab- and pembrolizumab-based combinations.
